Immune cell boost may keep leukemia at bay after transplant

NCT ID NCT07552649

Not yet recruiting Disease control Sponsor: Antonio Pierini Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests a stem cell transplant from a matched sibling donor combined with special immune cells (regulatory and conventional T cells) for people with high-risk acute myeloid leukemia (AML). The goal is to prevent the cancer from coming back. About 28 participants will receive this treatment and be followed for 2 years to see if they remain disease-free.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: stem cell transplant with regulatory and conventional T cells
What this could lead to: If successful, this approach could reduce the chance of leukemia returning after a stem cell transplant, offering better long-term control for high-risk patients.
What could go wrong: This is a small, early Phase 2 trial with only 28 participants, so results may not apply to everyone. There are risks of graft-versus-host disease, infection, or transplant failure.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for AML (ACUTE MYELOID LEUKEMIA) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

acute myeloid leukemia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

AML (ACUTE MYELOID LEUKEMIA)

Contacts and locations

Locations

Azienda Ospedaliera di Perugia - Ospedale S. Maria della Misericordia

Perugia, 06132, Italy
Presidio Ospedaliero Pescara - Azienda Sanitaria Locale di Pescara

Pescara, 65124, Italy

More trials for these conditions

Other studies related to the condition(s) this trial covers.